Open access
Open access
Powered by Google Translator Translator

[Abstract Only] Randomized Trial: DOAC Not as Good as Vitamin K Antagonist for Anticoagulation in Antiphospholipid Syndrome

15 Oct, 2019 | 10:32h | UTC

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries: Rivaroxaban Not Noninferior to VKAs for Antiphospholipid Antibody Syndrome – NEJM Journal Watch (free) AND DOAC Disappoints in Thrombotic Autoimmune Disorder – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

 

No spam, just news.